Anixa Biosciences, Inc.

As of July 31, 2026, Anixa Biosciences, Inc. carries a market capitalization of 101.85M, placing it among publicly traded companies globally. Its enterprise value stands at 88.88M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Anixa Biosciences, Inc.'s next confirmed earnings release is scheduled for January 6, 2027.

As of July 31, 2026, Anixa Biosciences, Inc. has 34.58M shares outstanding.

These figures are as of July 31, 2026.

As of July 31, 2026, Anixa Biosciences, Inc. maintains a current ratio of 8.54, meaning it holds 8.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended July 31, 2026, Anixa Biosciences, Inc. posted a negative return on equity (ROE) of -66.84, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -63.45, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 4.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Anixa Biosciences, Inc.'s stock has declined approximately 30.89% over the past 52 weeks. The 50-day moving average sits at 2.62, while the 200-day moving average is 2.56.

Over the twelve months ended July 31, 2026, Anixa Biosciences, Inc. generated - - in revenue and converted that into -9.00M in net income, yielding earnings per share of -0.27. EBITDA reached -9.48M, while operating income came in at -9.52M.

As of July 31, 2026, Anixa Biosciences, Inc. holds 12.02M in cash and equivalents against 150,892.80 in total debt, resulting in a net debt position of -1.21M. Total book value stands at 12.55M, with working capital of 11.42M providing operational flexibility.

Anixa Biosciences, Inc. produced -6.40M in operating cash flow over the twelve months ended July 31, 2026.

These figures cover the twelve months ended July 31, 2026. Free cash flow yield is negative at -6.48: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.44, meaning Anixa Biosciences, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Anixa Biosciences, Inc.'s most recent stock split took place on June 26, 2015 with a 25:1 split ratio.

As of July 31, 2026, Anixa Biosciences, Inc. has an Altman Z-Score of 12.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.